Head to Head Contrast: BioLineRx (NASDAQ:BLRX) & Entrada Therapeutics (NASDAQ:TRDA)

BioLineRx (NASDAQ:BLRXGet Free Report) and Entrada Therapeutics (NASDAQ:TRDAGet Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, earnings, analyst recommendations, risk and valuation.

Profitability

This table compares BioLineRx and Entrada Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioLineRx N/A -325.10% -86.48%
Entrada Therapeutics 14.42% 9.73% 4.80%

Valuation & Earnings

This table compares BioLineRx and Entrada Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioLineRx $4.80 million 10.33 -$60.61 million ($0.76) -0.82
Entrada Therapeutics $129.01 million 3.87 -$6.68 million $0.63 23.48

Entrada Therapeutics has higher revenue and earnings than BioLineRx. BioLineRx is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for BioLineRx and Entrada Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioLineRx 0 0 1 0 3.00
Entrada Therapeutics 0 0 2 0 3.00

BioLineRx presently has a consensus target price of $21.00, suggesting a potential upside of 3,287.10%. Entrada Therapeutics has a consensus target price of $21.00, suggesting a potential upside of 41.99%. Given BioLineRx’s higher probable upside, research analysts clearly believe BioLineRx is more favorable than Entrada Therapeutics.

Risk & Volatility

BioLineRx has a beta of 1.54, indicating that its share price is 54% more volatile than the S&P 500. Comparatively, Entrada Therapeutics has a beta of -0.23, indicating that its share price is 123% less volatile than the S&P 500.

Insider & Institutional Ownership

1.6% of BioLineRx shares are held by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are held by institutional investors. 1.1% of BioLineRx shares are held by company insiders. Comparatively, 7.6% of Entrada Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Entrada Therapeutics beats BioLineRx on 10 of the 13 factors compared between the two stocks.

About BioLineRx

(Get Free Report)

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

About Entrada Therapeutics

(Get Free Report)

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.